Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens

Clinical Infectious Diseases

Volumn 48, Issue 11, 2009, Pages 1526-1533

  Ho, Chao Chi ^a,b   Chen, Yee Chun ^a   Hu, Fu Chang ^a   Yu, Chong Jen ^a   Yang, Pan Chyr ^a   Luh, Kwen Tay ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; OFLOXACIN; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CONTROL GROUP; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DYSPEPSIA; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TIME SERIES ANALYSIS; TREATMENT OUTCOME; VOMITING; XEROSTOMIA; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; LIVER FAILURE; MIDDLE AGED; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; ASPARTATE AMINOTRANSFERASES; AZA COMPOUNDS; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; HEPATIC INSUFFICIENCY; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; QUINOLINES; STREPTOMYCIN; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 66949147659     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598929     Document Type: Article

References (28)

1. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-52.
2. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991;99:465-71.
3. Joint Tuberculosis Committee of the British Thoracic S. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-48.
4. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
5. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996;77:335-40.
6. Hwang SJ, Wu JC, Lee CN, et al. A prospective clinical study of iso- niazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997; 12:87-91.
7. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002;6:699-705.
8. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-7.
9. Ormerod LP, Horsfield N. Frequency and type of reactions to anti- tuberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996; 77:37-42.
10. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67:99-108.
11. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166:916-9.
12. Hsueh PR, Liu YC, So J, Liu CY, Yang PC, Luh KT. Mycobacterium tuberculosis in Taiwan. J Infect 2006; 52:77-85.
13. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyl- transferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35:883-9.
14. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998;2:265-71.
15. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-9.
16. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999; 44:393-5.
17. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxi- floxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-9.
18. Kahn JB. Latest industry information on the safety profile of levoflox- acin in the US. Chemotherapy 2001 ; 47(Suppl 3):32-7; discussion 44-8.
19. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26:940-50.
20. Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000;22:798-817; discussion 797.
21. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:331-8.
22. Centers for Disease Control, Republic of China (Taiwan). Guidelines for diagnosis and treatment of tuberculosis (Chinese). Available at: http://www.cdc.gov.tw/public/Attachment/87314324271.pdf. Accessed 24 December 2008.
23. Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127:1304-11.
24. Wong WM, Wu PC, Yuen M-F, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31:201-6.
25. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169:421-6.
26. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170:1131-4.
27. Pletz MWR, De Roux A, Roth A, Neumann K-H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48:780-2.
28. Blanc L, Chaulet P, Espinal M, et al. Treatment of tuberculosis: guidelines for national programmes. Document WHO/CDS/TB/2003.313. Geneva: World Health Organization, 2003.